Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 44
- Registration Number
- NCT01518920
- Locations
- 🇺🇸
Pfizer Investigational Site, Dallas, Texas, United States
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 39
- Registration Number
- NCT01511510
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Interferon beta-1a (current approved manufacturing process invloving FBS)Drug: Interferon beta-1a (new process, manufactured without FBS)
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2012-11-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 110
- Registration Number
- NCT01500408
- Locations
- 🇺🇸
Research Site, St. Paul, Minnesota, United States
A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes
- Conditions
- Chronic Kidney DiseaseType 2 Diabetes
- Interventions
- Drug: 20 mg bardoxolone methylDrug: Placebo
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 18
- Registration Number
- NCT01500798
BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis
- Conditions
- Lupus Nephritis
- Interventions
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 276
- Registration Number
- NCT01499355
- Locations
- 🇹🇭
Research Site, Patumwan, Bangkok, Thailand
An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 28
- Registration Number
- NCT01494701
- Locations
- 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸UT Southwestern Medical Center - Children's Medical Center Dallas, Dallas, Texas, United States
Canadian Avonex PEN Productivity Study
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2015-02-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 111
- Registration Number
- NCT01489748
- Locations
- 🇨🇦
Central Contact, Burlington, Ontario, Canada
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Biogen
- Target Recruit Count
- 231
- Registration Number
- NCT01485003
- Locations
- 🇺🇸
Research Site, Tacoma, Washington, United States
An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice
- First Posted Date
- 2011-11-28
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 4734
- Registration Number
- NCT01480063
- Locations
- 🇪🇸
Site Research, Bilbao, Vizcaya, Spain
🇪🇸Research site, San Cristobal de La laguna, Tenerife, Spain
🇨🇦Reasearch Center, London, Ontario, Canada
Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis
- First Posted Date
- 2011-11-28
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 901
- Registration Number
- NCT01480076
- Locations
- 🇬🇧
Research Site, London, United Kingdom